Ikena Oncology Stock Analysis
| IKNA Stock | USD 1.73 0.03 1.76% |
Ikena Oncology is undervalued with Real Value of 5.55 and Target Price of 17.0. The main objective of Ikena Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Ikena Oncology is worth, separate from its market price. There are two main types of Ikena Oncology's stock analysis: fundamental analysis and technical analysis.
The Ikena Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ikena Oncology's ongoing operational relationships across important fundamental and technical indicators.
Ikena |
Ikena Stock Analysis Notes
About 64.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ikena Oncology recorded a loss per share of 1.23. The entity had not issued any dividends in recent years. Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To learn more about Ikena Oncology call Mark Manfredi at 857 273 8343 or check out https://ikenaoncology.com.Ikena Oncology Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ikena Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ikena Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Ikena Oncology generated a negative expected return over the last 90 days | |
| Ikena Oncology may become a speculative penny stock | |
| Ikena Oncology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.16 M. Net Loss for the year was (68.17 M) with loss before overhead, payroll, taxes, and interest of (48.7 M). | |
| Ikena Oncology currently holds about 192.81 M in cash with (79.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ikena Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Ikena Oncologys Buy Rating Reaffirmed at HC Wainwright |
Ikena Oncology Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ikena Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ikena Largest EPS Surprises
Earnings surprises can significantly impact Ikena Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-12 | 2022-03-31 | -0.42 | -0.47 | -0.05 | 11 | ||
2024-11-07 | 2024-09-30 | -0.27 | -0.21 | 0.06 | 22 | ||
2024-08-08 | 2024-06-30 | -0.35 | -0.28 | 0.07 | 20 |
Ikena Stock Institutional Investors
| Shares | Sofinnova Ventures | 2024-06-30 | 382.6 K | Blackrock Inc | 2024-06-30 | 354.8 K | Millennium Management Llc | 2024-06-30 | 354.7 K | Goldman Sachs Group Inc | 2024-06-30 | 273.8 K | Geode Capital Management, Llc | 2024-06-30 | 256.7 K | Citadel Advisors Llc | 2024-06-30 | 244.7 K | Two Sigma Investments Llc | 2024-06-30 | 236.9 K | Barclays Plc | 2024-06-30 | 196 K | Two Sigma Advisers, Llc | 2024-06-30 | 173.2 K | Bvf Inc | 2024-09-30 | 4.8 M | Blue Owl Capital Holdings Lp | 2024-06-30 | 4.1 M |
Ikena Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 83.49 M.Ikena Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.45) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.40) | (0.38) |
Management Efficiency
Ikena Oncology has return on total asset (ROA) of (0.2206) % which means that it has lost $0.2206 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3709) %, meaning that it created substantial loss on money invested by shareholders. Ikena Oncology's management efficiency ratios could be used to measure how well Ikena Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Ikena Oncology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.7 M, whereas Other Current Assets are forecasted to decline to about 2.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.07 | 4.27 | |
| Tangible Book Value Per Share | 4.07 | 4.27 | |
| Enterprise Value Over EBITDA | 0.36 | 0.38 | |
| Price Book Value Ratio | 0.48 | 0.51 | |
| Enterprise Value Multiple | 0.36 | 0.38 | |
| Price Fair Value | 0.48 | 0.51 | |
| Enterprise Value | -26.9 M | -25.6 M |
Leadership effectiveness at Ikena Oncology is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin (97.55) | Beta 0.485 | Return On Assets (0.22) | Return On Equity (0.37) |
Technical Drivers
As of the 22nd of November, Ikena Oncology retains the Downside Deviation of 1.7, market risk adjusted performance of 0.0174, and Risk Adjusted Performance of 0.0119. Ikena Oncology technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Ikena Oncology Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ikena Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ikena Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ikena Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ikena Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ikena Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ikena Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ikena Oncology Outstanding Bonds
Ikena Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ikena Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ikena bonds can be classified according to their maturity, which is the date when Ikena Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| iHeartCommunications 6375 percent Corp BondUS45174HBC07 | View | |
| iHeartCommunications 8375 percent Corp BondUS45174HBD89 | View | |
| iHeartCommunications 525 percent Corp BondUS45174HBE62 | View | |
| iHeartCommunications 475 percent Corp BondUS45174HBG11 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Ikena Oncology Predictive Daily Indicators
Ikena Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ikena Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ikena Oncology Forecast Models
Ikena Oncology's time-series forecasting models are one of many Ikena Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ikena Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ikena Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ikena Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ikena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ikena Oncology. By using and applying Ikena Stock analysis, traders can create a robust methodology for identifying Ikena entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (7.46) | (7.83) | |
| Operating Profit Margin | (8.23) | (8.64) | |
| Net Loss | (7.44) | (7.81) | |
| Gross Profit Margin | (5.51) | (5.79) |
Current Ikena Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ikena analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ikena analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 17.0 | Buy | 3 | Odds |
Most Ikena analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ikena stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ikena Oncology, talking to its executives and customers, or listening to Ikena conference calls.
Ikena Stock Analysis Indicators
Ikena Oncology stock analysis indicators help investors evaluate how Ikena Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ikena Oncology shares will generate the highest return on investment. By understating and applying Ikena Oncology stock analysis, traders can identify Ikena Oncology position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 60.8 M | |
| Common Stock Shares Outstanding | 41.7 M | |
| Total Stockholder Equity | 169.8 M | |
| Tax Provision | -162 K | |
| Property Plant And Equipment Net | 8 M | |
| Cash And Short Term Investments | 175.5 M | |
| Cash | 119.9 M | |
| Accounts Payable | 2.1 M | |
| Net Debt | -109.2 M | |
| 50 Day M A | 1.7067 | |
| Total Current Liabilities | 14.2 M | |
| Other Operating Expenses | 84.6 M | |
| Non Current Assets Total | 13.4 M | |
| Non Currrent Assets Other | 5.4 M | |
| Stock Based Compensation | 7.6 M |
Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |